Latest News and Press Releases

Longeveron (LGVN), developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, reported 1Q26 financial results.

Longeveron announces Data Monitoring Committee for Phase 2b clinical trial in HLHS completed a risk-benefit assessment and recommended continuation.

New York, USA, May 05, 2026 (GLOBE NEWSWIRE) -- Global Stem Cell Therapy Market Set to Flourish at a CAGR of ~11% by 2034 Owing to the Technological Advancements and Favorable Regulations |...

Longeveron reported financial results for the year ended December 31, 2025 and provided a business update. Results from pivotal P2 trial anticipated 3Q26.

Longeveron announces closing of previously announced up to $30 million private placement.

Longeveron announces private placement financing of up to $30 million.

Results of Phase 2b clinical trial demonstrating stem cell therapy improved condition of patients with aging frailty published in Cell Stem Cell journal.

Longeveron supports the passing of the Mikaela Naylon Give Kids a Chance Act which reauthorizes the Rare Pediatric Disease Priority Review Voucher Program.

Japan Patent Office (JPO) has granted Longeveron a patent covering potency assay methods for assessing human mesenchymal stem cells (MSCs).

Longeveron granted FDA Type C meeting ahead of Q3 2026 data readout of pivotal clinical trial for stem cell therapy in hypoplastic left heart syndrome.